The Company declared a Final Dividend @ 3.50 Rupees on each Equity Share.
POLYMED · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 5.6 pts less than Nifty Smallcap 250 and 4.8 pts less than its Medical Equipment & Supplies peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Poly Medicure Ltd's Board approved the audited financial results for Q4 and FY ended March 31, 2026. Standalone revenue from operations grew to Rs. 44,301.49 lakhs for Q4 and Rs. 1,78,238.25 lakhs for full year. Consolidated total income reached Rs. 55,226.79 lakhs for FY2026, up from Rs. 46,513.77 lakhs in FY2025. The Board recommended a final dividend of Rs. 3.5 per equity share (70% payout on Rs. 5 face value) for FY2025-26, subject to shareholder approval at the AGM. Standalone net profit after tax for FY2026 stood at Rs. 33,598.49 lakhs with EPS of Rs. 33.15. The company also completed two significant acquisitions during the year - Pendracare Group (90% economic rights) and Medlstream SA/Citieffe Group (100% economic rights).
The company delivered strong financial growth with improved profitability and recommends a healthy 70% dividend payout, which is positive for shareholders. The stock may see positive reaction given robust earnings growth and consistent shareholder returns.